# Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax™) to the Drug (Everolimus) -Eluting Stent (Synergy™) in Acute Coronary Syndrome

> **NCT02049229** · PHASE4 · UNKNOWN · sponsor: **The Hospital District of Satakunta** · enrollment: 1800 (estimated)

## Conditions studied

- Myocardial Infarction
- Percutaneous Coronary Intervention
- Atherosclerosis

## Interventions

- **DEVICE:** percutaneous coronary intervention
- **DEVICE:** percutaneous coronary intervention

## Key facts

- **NCT ID:** NCT02049229
- **Lead sponsor:** The Hospital District of Satakunta
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-01
- **Primary completion:** 2015-10
- **Final completion:** 2019-10
- **Target enrollment:** 1800 (ESTIMATED)
- **Last updated:** 2015-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02049229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02049229, "Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax™) to the Drug (Everolimus) -Eluting Stent (Synergy™) in Acute Coronary Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02049229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*